Zydus Lifesciences announced that the U.S. Food and Drug Administration (USFDA) has granted Fast Track Designation to Usnoflast (ZYIL1), a novel oral NLRP3 inhibitor, for the treatment of Amyotrophic ...

Those with ALS have an average survival of around two to five years from diagnosis, with most ALS patients dying from ...

Zydus Lifesciences' impactful campaign promotes self-breast examination for early detection of breast cancer, reaching ...

The ‘Easiest Exam’ campaign promotes early detection of breast cancer, amassing over 164 million impressions and encouraging ...

Zydus Lifesciences is innovating a single-device for semaglutide. This device can deliver multiple strengths of the drug. It ...

Sagar Doshi of Nuvama Professional Clients Group recommends these three stocks today - Chennai Petroleum Corporation Ltd, ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company, has announced that the USFDA has granted ‘Fast Track ...

Zydus Lifesciences has received final approval from the USFDA to launch its isotretinoin capsules USP in six different ...

Devan Choksey is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1069 in its research report dated May 26, 2025.

Zydus Lifesciences consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter ...

The pharma companys Board has recommended a final dividend of Rs 11 per equity share of face value Rs 1 each, representing a ...

Results: Net profit for the quarter fell 1% from the year-ago period to ₹1,171 crore. The company reported a one-time loss of ...